ARYx Therapeutics Inc.  (ARYX) Trade Now »     Rate ARYX  -  Discuss ARYX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

ARYX: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Extreme FDA Calendar Trades: 18 Stocks Under $5 ARYX

73%

-47.12% in 6 days (closed on 07/09/09) <> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio... Continue reading »

FDA Calendar Updates: BDSI is Worth the Wait, Zicam Warning ARYX

73%

-1.53% in 17 days (closed on 07/03/09) <> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st... Continue reading »

From the Blogosphere

Unusual 11 Mid-Day Movers 7/8: NVGN, GRVY, TRGT, AMGN Higher; ARYX, RODM, YRCW, GNW Lower

Novogen Limited (Nasdaq: NVGN) <font>62.5% HIGHER;</font> continuing higher today following a 37% rally yesterday on news that researchers have discovered that Marshall Edwards (Nasdaq: MSHL) anti-tumor drug phenoxodiol kills rapidly proliferating t-cells.Gravity Co., Ltd (Nasdaq: GRVY) <font>50.9% HIGHER;</font> reports Q1 revenues rose 9.3% from last year to $12.99 million. Net income rose to $4.1 million from $1.29 million.ARYx Therapeutics, Inc. (NASDAQ: ARYX) <font>44.5 LOWER;</font> getting slammed in pre-open trading after announcing that a trial of anticoagulant agent tecarfarin did... Continue reading »

Morning Movers 7/8: TRGT, HNAB, AMGN, NTWK, FDO Higher; ARYX, XNPT, ARNA, AXL Lower

ARYx Therapeutics, Inc. (NASDAQ: ARYX) <font>54.9% LOWER;</font> getting slammed in pre-open trading after announcing that a trial of anticoagulant agent tecarfarin did not achieve the primary endpoint of superiority over leading oral anticoagulant warfarin. Click here for the full report.Targacept, Inc. (Nasdaq: TRGT) <font>43.4% HIGHER;</font> announced that AstraZeneca (NYSE: AZN) has informed Targacept that it plans to conduct further development of AZD3480 (TC-1734) for attention deficit/hyperactivity disorder and has agreed to make a $10 million milestone payment to Targacept.Hana Bio... Continue reading »

Unusual 11 Mid-Day Movers 12/18: ARYX, GIII, MU, XL Higher; CPY, ADLR, TTWO, SIMG Lower

ARYx Therapeutics, Inc. (NASDAQ: ARYX) 75.4% HIGHER; today announced successful top-line efficacy results from a Phase 2b clinical trial testing the safety and efficacy of its oral anti-arrhythmic therapy, ATI-2042, in patients with atrial fibrillation. By achieving statistical significance at the two highest doses of the three tested, the results essentially mirrored the findings of an earlier Phase 2 study also conducted in paroxysmal atrial fibrillation patients. Complete results from this study are expected in the first quarter of 2009. The primary efficacy analysis was the percent chan... Continue reading »

After-Hours Movers 7/2: NVIDIA (NVDA) Slammed on Q2 Warning, ARYx (ARYX) Lower After P&G Walks From Partnership

StreetInsider.com After-Hours Movers:NVIDIA Corporation (Nasdaq: NVDA) 21% LOWER; sees Q2 revenue of $875 million to $950 million, below the consensus of $1.1 billion. The estimated decrease in revenue and gross margin is due to several reasons: end-market weakness around the world, the delayed ramp of a next generation MCP, and price adjustments of our GPU products to respond to competitive products.TranS1 Inc. (Nasdaq: TSON) 18% LOWER; announced that revenues for the second quarter of 2008 are expected to be approximately $5.9 to $6.0 million, lower than previously announced guidance of $... Continue reading »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.